ESTRO Guide 2018

Pre-Meeting Courses

CLINICAL PRE-MEETING COURSE

INTERDISCIPLINARY PRE-MEETING COURSE Combined SBRT and targeted- immune therapies: biological and clinical perspectives

Radiation for lymphoma: updated role, new guidelines and present/ future developments Joint ESTRO-ILROG

FRIDAY 20 APRIL 2018 Course directors: U. Ricardi (IT) and J. Yahalom (USA)

FRIDAY 20 APRIL 2018 Course directors: E. Lartigau (FR) and A. Yaromina (NL)

improving their knowledge in lymphoma modern radiation therapy, including the combination of radiation with new systemic treatments strategies.

COURSE AIM To provide an update on the evolving role of radiation therapy in malignant lymphoma, new guidelines and technologies, integration with new regimens with emphasis on immunotherapy. LEARNINGOBJECTIVES • To discuss modern treatment options with or without radiation therapy across the spectrum of lymphoma scenarios • To recognise the impact of metabolic imaging on staging, response criteria, treatment options and field design • To discuss the advantages and challenges of modern radiation technology (including protons) in treating lymphoma • To explain the rapidly changing use of conventional and new systemic treatments • To engage in the new field of immunotherapy for lymphoma and interaction with radiation therapy. WHO SHOULD ATTEND? Practising radiation oncologists, radiation and clinical oncology trainees, clinical oncologists, medical oncologists, haematologists, physicists, radiation oncology nurses interested in learning and

COURSE AIM To provide an overview of the current and potential future role of SBRT in combination with targeted and immunotherapies in translational research and clinical practice. LEARNINGOBJECTIVES • To summarise radiobiological effects of high dose per fraction on tumour and normal tissues • To assess the clinical effectiveness of SBRT in different tumour sites • To identify the limitations of SBRT • To define the biological mechanisms for the rational combination of targeted and immune therapies with high dose fractions • To assess the clinical effectiveness of SBRT combined with systemic targeted /immune therapies in different tumour site including cancers of the lung, liver and gastrointestinal tract • To discuss with experts, future research and clinical implementation.

CONTENT Introduction • Role of radiotherapy across the spectrum of lymphoma histologies and stages • Updates on classification, imaging, staging and response criteria • Systemic therapies - old regimens and new agents. Hodgkin Lymphoma • Early • Advanced • Salvage • Principles of new field guidelines. Non Hodgkin Lymphomas • Indolent • Aggressive • ENL. Technology • Cutting edge technologies with photons: IMRT and DIBH • Protons: pros and caveats. Immunotherapy

CONFERENCES

WHO SHOULD ATTEND? Radiation oncologists, senior residents and radiobiologists who are interested in learning

122